BeyondSpring, Inc. - Rasio nilai perusahaan marang dodolan BYSI

Simbol resmi perusahaan beyondspringpharma.com (BYSI)

Contract manufacturing plants are already ensuring the production of oncology drug batches for regulatory stages. The EV/Sales ratio of BeyondSpring Inc. (BYSI) reflects current dynamics, with the indicator standing at 0.00. The business relies on the outsourcing of testing and synthesis through third-party CRO/CMOs. Meanwhile, the high scalability of molecule rights allows for the efficient capture of global niches by utilizing external capacities for mass production.

BeyondSpring Inc (BYSI): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 19.11.2026

BeyondSpring Pharma - rincian analitis lan metrik utama (BYSI)

Pambiji fundamental perusahaan:BYSI, beyondspringpharma.com
Produk sing diprodhuksi BeyondSpring, Inc.

The investment status of BeyondSpring Inc. (BYSI) is determined by the balance between expectations for new drugs and the need for capital to fund clinical trials. An analysis of the EV/Sales ratio allows for an assessment of the business value relative to revenue, accounting for net debt, which reveals the company's dependence on external financing and liquidity risks in the event of potential regulatory rejections, both of which are critical for capital stability.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CHRS (Coherus BioSciences Inc.)|CRBP: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cardiff Oncology Corp (CRDF)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales